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Background
A subset of T cells with immunosuppressive properties is
the CD4+CD25+FOXP3+ regulatory T cells (Treg). Two
main hypotheses explain Tregs in HIV-1 infection: one
stating that Tregs prevent chronic immune activation, and
hence are beneficial, and another regarding Tregs as harm-
ful because they suppress anti-HIV immune responses. To
gain more information on the role of Tregs in chronic
HIV-1 infection, we are evaluating the Treg population in
chronic HIV-1 infected patients on HAART, treatment
naïve viremic patients, and HIV-1 infected Elite Control-
lers (EC). Additionally, as Tregs are known to inhibit T cell
activation, the T cell activation profile is also being tested.
Methods
PBMCs from 10 HAART patients and 10 ECs were tested.
To identify Tregs, PBMCs were subjected to staining and
flow cytometry using following antibodies: CD3, CD4,
CD25, CD127, and FOXP3. To recognize the activation
profile the following antibodies will be used: CD3, CD4,
CD69, Ki67, CD38, HLA-DR, and FOXP3.
Results
Our data in this ongoing study show that Tregs constitute
a smaller fraction of CD4+ T cells in ECs than in HAART
patients with median 1.46% (range 1.39 – 4.07) and 3.9%
(range 1. 82 – 9.61), respectively. Furthermore, evaluating
data in regards to CD25, FOXP3 and CD127low, another
way to identify Tregs, also showed a lower frequency of
Tregs in ECs compared with HAART patients, median
1.22% (range 0.07 – 2.70) and 3.10% (range 1.60 – 8.49),
respectively.
Conclusion
To date, we have found lower frequencies of Tregs in ECs
than in HAART patients. Seen in the light of ECs ability to
control HIV-1 infection and studies showing polyfunc-
tional CD8+ T cell responses in ECs, these data support a
harmful role of Tregs in the HIV-1 infected patient, e.g. by
suppressing HIV-1 specific CD8+ T cell responses.
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